Researchers find genetic factors that cause muscle weakness, wasting disorder

July 11, 2017 by Doug Bennett

For years, the underlying process that causes a debilitating muscle disorder in infants and young children has been largely unknown. Now, a group that includes University of Florida Health genetics researchers has identified the fundamental mechanism that causes congenital myotonic dystrophy.

The researchers have also developed specialized mouse models that will allow potential drug therapies to be tested. Taken together, the findings are a crucial step in addressing a disorder that arises from abnormally expanded stretches of repeats in DNA that alter muscle and brain development. The findings are published today in the journal Genes & Development.

Researchers now have a better understanding of how the misregulation of developmental genetic "switches" in unborn children gives rise to congenital myotonic dystrophy, said Maurice Swanson, Ph.D., a professor in the UF College of Medicine's department of molecular genetics and microbiology and associate director of the UF Center for NeuroGenetics.

"The ultimate goal is to come up with ideas for treating children with this disease soon after birth to minimize the long-term effects of the disorder," Swanson said.

In addition to severe muscle weakness, congenital myotonic dystrophy patients can have respiratory problems and intellectual deficits. The disorder is estimated to affect one out of every 3,500 to 16,000 individuals.

Within cells, messenger RNA molecules receive instructions from DNA and carry out protein-building activities. Using human muscle tissue samples, the researchers found that severe RNA misprocessing is a major cause of . Specifically, they identified several abnormalities in the genetic coding process that give rise to the disease, including one that affects the way in which a single gene produces multiple proteins.

Using mouse models that mimic the disease in humans, the researchers also showed disruption of a particular protein during prenatal development results in muscle at birth. Devising mouse models that replicate the effects of congenital myotonic dystrophy is especially important because there are limitations, including limited sample availability, to studying the disease in human tissue, Swanson said.

Altogether, the results show that disrupting certain RNA processing activities before birth alters the genetic switches that are essential for tissue development. That is significant because knowing where and when congenital myotonic dystrophy arises within genes is an important first step on the road to a potential cure, Swanson said.

"This provides us important new information about where we should go next and what kinds of therapeutics might be effective against this hereditary disease," Swanson said.

Explore further: Designed proteins to treat muscular dystrophy

Related Stories

Designed proteins to treat muscular dystrophy

June 28, 2017
The cell scaffolding holds muscle fibers together and protects them from damage. Individuals who suffer from muscular dystrophy often lack essential components in this cell scaffold. As a result, their muscles lack strength ...

Researchers find genetic cause of new type of muscular dystrophy

February 9, 2017
A newly discovered mutation in the INPP5K gene, which leads to short stature, muscle weakness, intellectual disability, and cataracts, suggests a new type of congenital muscular dystrophy. The research was published in the ...

New target may slow disease progression in Duchenne muscular dystrophy

September 12, 2016
Duchenne muscular dystrophy is a chronic disease causing severe muscle degeneration that is ultimately fatal. As the disease progresses, muscle precursor cells lose the ability to create new musclar tissue, leading to faster ...

Study sheds light on underlying causes of impaired brain function in muscular dystrophy

August 8, 2012
University of Florida researchers have identified a gene responsible for brain-related symptoms of the most common form of adult-onset muscular dystrophy.

Study identifies potential drug targets for muscular dystrophy treatments

January 9, 2017
Myotonic dystrophy type I (MD1) is a common form of muscular dystrophy associated with muscle wasting, weakness, and myotonia. These symptoms are linked to the accumulation of toxic gene transcripts in muscle cells that result ...

Cancer drug shows promise in reducing toxic genetic material in myotonic dystrophy

December 10, 2015
A group of researchers has shown for the first time in cells and in a mouse model that a drug used to treat cancer can neutralize the toxic RNA that causes the prolonged muscle contractions and other symptoms of myotonic ...

Recommended for you

Forgotten strands of DNA initiate the development of immune cells

September 21, 2017
Intricate human physiological features such as the immune system require exquisite formation and timing to develop properly. Genetic elements must be activated at just the right moment, across vast distances of genomic space.

Study reveals an ancient Achilles heel in the human genome

September 21, 2017
In a major study published today, researchers at deCODE genetics use whole-genome data from 14,000 people from across the population of Iceland, including 1500 sets of parents and children, to provide the most detailed portrait ...

Genome editing reveals role of gene important for human embryo development

September 20, 2017
Researchers have used genome editing technology to reveal the role of a key gene in human embryos in the first few days of development. This is the first time that genome editing has been used to study gene function in human ...

A piece of the puzzle: Eight autism-related mutations in one gene

September 19, 2017
Scientists have identified a hotspot for autism-related mutations in a single gene.

Scientists identify key regulator of male fertility

September 19, 2017
When it comes to male reproductive fertility, timing is everything. Now scientists are finding new details on how disruption of this timing may contribute to male infertility or congenital illness.

New assay leads to step toward gene therapy for deaf patients

September 18, 2017
Scientists at Oregon State University have taken an important step toward gene therapy for deaf patients by developing a way to better study a large protein essential for hearing and finding a truncated version of it.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.